Brief: CNS Pharma Receives Approval In Spain For Study Of Berubicin For Treatment Of Glioblastoma Multiforme

CNS Pharmaceuticals

28/04/2022 13:51

April 28 (Reuters) - CNS Pharmaceuticals Inc  CNSP.O :
    * CNS PHARMACEUTICALS RECEIVES APPROVAL FROM ETHICS
COMMITTEE AND
COMPETENT AUTHORITY IN SPAIN FOR POTENTIALLY PIVOTAL STUDY OF
BERUBICIN FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME (GBM)

Source text for Eikon:  ID:nPn8DC0Dfa 
Further company coverage:  CNSP.O 

 ((Reuters.Briefs@thomsonreuters.com;))